TFs and effector molecules expression coupled with the progression of sequential NK cell stages along the in vitro trajectory. (A) Representative FACS gating scheme to define S1/2 (Lin−CD34+CD161−CD56−CD94−), S3a (Lin−CD34−CD161+CD45RA+CD56−CD94−), S3b-NKp44− (Lin−CD34−CD56+CD94−NKp44−), S3b-NKp44+ (Lin−CD34−CD56+CD94− NKp44+DNAM-1hiCD161lo), ILC3 (Lin−CD34−CD56+CD94−NKp44+DNAM-1loCD161hi), and S4 (Lin−CD34−CD56+CD94+) populations generated in vitro from Lin−CD34+ progenitors collected from cultures at 2 weeks (S1/2 and S3a) and 4 weeks (S3b-NKp44+, S3bNKp44−, ILC3, S4). (B) Violin plots display intracellular expression of GZMB and PRF1 within the subsets S3a, S3b-NKp44−, S3b-NKp44+, S4, and ILC3, from a combined pool of 3 donors. Statistical significance was performed with Kruskal-Wallis test between pair-wise comparisons S4 NK vs all other subsets. (C) Representative FACS histograms of TBET, EOMES, and RORγt expression within the subsets S3a, S3b-NKp44−, S3b-NKp44+, S4, and ILC3. Values described mean fluorescence intensity (MFI) of each indicated population. (D) Secretion of IFN-γ and IL-22 by in vitro–generated NK-S3b, NK-S4, and ILC3 cells after 4-week culture in response to stimulations with either PMA/ionomycin, IL-12/15/18, or IL-2/1β/23 compared with untreated cells (UT). Statistical significance was performed with 1-way analysis of variance (ANOVA) between all subsets (n = 9). (E) Upregulation of CD107a by in vitro generated NK-S3b (left panels), NK-S4 (middle panels) and ILC3 (right panels) cells after 4-week culture in response to stimulations with either PMA/ionomycin or K562 target cell (with effector-to-target [E:T] ratio of 1:5), compared with UT cells as controls (n = 3 individual donors, with 3 replicates for each donors). (F) Upregulation of CD107a by in vitro–generated NK cells after 2 weeks of further expansion on mbIL21-41BBL-K562 feeder cells, stimulated with K562 target cells. Resting peripheral blood (PB) NK cells were used as reference control and CB-derived in vitro expanded NK cells were separated into NK-S3b and NK-S4 stages. FACS plots show representative CD107a expression and bar plots represent the proportion of CD107a positive NK cells from PB NK cells and in vitro generated expanded NK cells (n = 3 donors). (G) IFN-γ secretion in response to K562 target cell stimulation from the same experiment settings as described in panel F. (F-G) Statistical significance was performed with t test;∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001; and n.s., not significant.

TFs and effector molecules expression coupled with the progression of sequential NK cell stages along the in vitro trajectory. (A) Representative FACS gating scheme to define S1/2 (LinCD34+CD161CD56CD94), S3a (LinCD34CD161+CD45RA+CD56CD94), S3b-NKp44 (LinCD34CD56+CD94NKp44), S3b-NKp44+ (LinCD34CD56+CD94 NKp44+DNAM-1hiCD161lo), ILC3 (LinCD34CD56+CD94NKp44+DNAM-1loCD161hi), and S4 (LinCD34CD56+CD94+) populations generated in vitro from LinCD34+ progenitors collected from cultures at 2 weeks (S1/2 and S3a) and 4 weeks (S3b-NKp44+, S3bNKp44, ILC3, S4). (B) Violin plots display intracellular expression of GZMB and PRF1 within the subsets S3a, S3b-NKp44, S3b-NKp44+, S4, and ILC3, from a combined pool of 3 donors. Statistical significance was performed with Kruskal-Wallis test between pair-wise comparisons S4 NK vs all other subsets. (C) Representative FACS histograms of TBET, EOMES, and RORγt expression within the subsets S3a, S3b-NKp44, S3b-NKp44+, S4, and ILC3. Values described mean fluorescence intensity (MFI) of each indicated population. (D) Secretion of IFN-γ and IL-22 by in vitro–generated NK-S3b, NK-S4, and ILC3 cells after 4-week culture in response to stimulations with either PMA/ionomycin, IL-12/15/18, or IL-2/1β/23 compared with untreated cells (UT). Statistical significance was performed with 1-way analysis of variance (ANOVA) between all subsets (n = 9). (E) Upregulation of CD107a by in vitro generated NK-S3b (left panels), NK-S4 (middle panels) and ILC3 (right panels) cells after 4-week culture in response to stimulations with either PMA/ionomycin or K562 target cell (with effector-to-target [E:T] ratio of 1:5), compared with UT cells as controls (n = 3 individual donors, with 3 replicates for each donors). (F) Upregulation of CD107a by in vitro–generated NK cells after 2 weeks of further expansion on mbIL21-41BBL-K562 feeder cells, stimulated with K562 target cells. Resting peripheral blood (PB) NK cells were used as reference control and CB-derived in vitro expanded NK cells were separated into NK-S3b and NK-S4 stages. FACS plots show representative CD107a expression and bar plots represent the proportion of CD107a positive NK cells from PB NK cells and in vitro generated expanded NK cells (n = 3 donors). (G) IFN-γ secretion in response to K562 target cell stimulation from the same experiment settings as described in panel F. (F-G) Statistical significance was performed with t test;∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001; and n.s., not significant.

Close Modal

or Create an Account

Close Modal
Close Modal